TXMD stock: buy or sell?

TXMD stock price: $2.49 1.22% At close on June 26th, 2019

Updated on:
June 26th, 2019

1

TherapeuticsMD shares stepped up 1.22% to $2.49 today. On June 17th TXMD skyrocketed an astounding 8.27%. On Jun/24 TXMD collapsed a hair-raising -6.00%.

TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Should I buy TXMD stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, TherapeuticsMD stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean TXMD will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is TherapeuticsMD stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we collected 6 ratings published for TXMD stock in the last 30 days.

The general sentiment of these ratings is bullish for TXMD stock, with 5 positive ratings.
Is TXMD a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-12Cantor Fitzgeraldn/aOverweight
2019-6-11JPMorgan Chase & Co.n/aOverweight
2019-6-11Cowenn/aOutperform
2019-5-7Jefferies Financial Groupn/aHold
2019-2-12$1n/aBuy
2019-2-11Oppenheimern/aBuy

TXMD stock analysis

Daily outlook

Shares of TherapeuticsMD closed today at $2.49 and stepped up a nice 1.22%.

TherapeuticsMD stepped up a nice 1.22% and closed at $2.49. TXMD is soaring again after a 12.90% correction from its last top on June 19th at $2.79.

TXMD stock chart (daily)

Weekly outlook

After boosting a super good 7.92% in a week last week, TherapeuticsMD closed this week at $2.49 and plummed a bloodcurdling -6.04%.

TXMD stock chart (weekly)

TXMD stock price history

TXMD stock went public on October 5th, 2017 with a price of $5.151. Since then, TXMD stock sliced a -51.70%, with a yearly average of -51.70%.

1: Adjusted price after possible price splits or reverse-splits.

TXMD stock historical price chart

TXMD stock reached 52-week highs at $7.18, and all-time highs 2018-06-08 with a price of 7.66.

TXMD stock price target is $10.00

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' TXMD stock price predictions in the hope that they will be met as they may be wrong and not met. We have 6 price targets for TherapeuticsMD stock released in the last month:
TXMD stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-12Cantor FitzgeraldReiterates$27.00$13.00-51.9%
2019-6-11JPMorgan Chase & Co.Lowers Target$8.00$6.00-25%
2019-6-11CowenReiterates$16.00$9.00-43.8%
2019-5-7Jefferies Financial GroupLowers Target$5.00$4.00-20%
2019-2-12$1Reiteratesn/a$14.00-
2019-2-11OppenheimerSet Price Targetn/a$14.00-
(in average)$14.00$10.00-29.0%
Moving in a range from $14.00 and $4.00, the price target for TherapeuticsMD stock is $10.00. In average, analysts' outlook on TXMD price forecast is negative, downsizing the forecast by a -29.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on February, TherapeuticsMD plummed a scary -51.08%. As soon as we get its actual EPS from the earnings report, we will update this review.
TXMD earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.11n/a
2017-Q2-n/a-0.1n/a
2017-Q32017-11-01-0.1n/an/a
2017-Q42018-02-20-0.09-0.1n/a
2018-Q12018-05-03-0.1-0.11n/a
2018-Q22018-07-30-0.12-0.15n/a
2018-Q32018-11-07-0.22-0.16n/a
2018-Q42019-02-21-0.17-0.17n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, TherapeuticsMD annual sales depreciated an awful -4.04% to $16.10 million USD from $16.78 marked in 2017. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) plunged a -365.24% to -823.73%.

TXMD annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$8.78 M-$-28.42 M-323.7%-
2014$15 M71.14%$-54.22 M-360.8%90.77%
2015$20 M34.05%$-85.08 M-422.4%56.92%
2016$19 M-3.90%$-89.88 M-464.3%5.64%
2017$17 M-13.32%$-76.93 M-458.5%-14.41%
2018$16 M-4.04%$-132.62 M-823.7%72.40%

Quarterly financial results

TherapeuticsMD posted $5.09 M in revenues for 2018-Q4, a 46.52% improvement compared to previous quarter. Reported quarter income marked $-39.39 million with a profit margin of -773.96%. Profit margin boosted a 251.08% compared to previous quarter when profit margin was -1,025.04%. When comparing sales to same quarter last year, TherapeuticsMD sales marked a super good increase and climbed a 23.41%.
TXMD quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$4 M-$-21.16 M-530.3%-
2017-Q2$4 M6.52%$-19.68 M-463.1%-6.99%
2017-Q3$4 M3.94%$-14.66 M-332.0%-25.48%
2017-Q4$4 M-6.64%$-21.43 M-519.5%46.12%
2018-Q1$4 M-8.51%$-24.40 M-646.7%13.88%
2018-Q2$4 M-0.28%$-33.22 M-882.8%36.13%
2018-Q3$3 M-7.69%$-35.61 M-1025.0%7.18%
2018-Q4$5 M46.52%$-39.39 M-774.0%10.63%

TherapeuticsMD ownership

When you are planning to invest in shares of a stock, it's worth to check its ownership structure.

TherapeuticsMD shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 17.76% of all shares.

In case of TherapeuticsMD stock, 78.61% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TXMD stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to TherapeuticsMD:

TXMDABBVAGRXAMAGLCI
Market cap$600.6 M$97.2 B$63.0 M$311.7 M$215.3 M
Total shares241.2 M1,480.0 M43.7 M33.8 M37.9 M
Float shares198.7 M1,480.0 M25.5 M21.9 M24.3 M
  - Institutional holdings (%)78.6%71.9%54.2%121.2%86.6%
  - Insider holdings (%)17.8%0.1%1.3%2.1%28.2%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

TXMD summary

Wednesday, June 26th, 2019
Open$2.48
Close$2.49
Day range$2.38 - $2.52
Previous close$2.46
Session gain1.22%
Average true range$0.27
50d mov avg$3.37
100d mov avg$4.36
200d mov avg$4.74
Daily patternlb01a
Weekly pattern lb06a

TherapeuticsMD performance

To better understand TherapeuticsMD performance you must compare its gains with other related stocks in same sector or industry. We compared TherapeuticsMD against AbbVie, Agile Therapeutics, AMAG Pharmaceuticals, Lannett and Pfizer in the following table:
Stock3m6m12m
TXMDTherapeuticsMD-48.87%-36.48%-60.10%
ABBVAbbVie-17.40%-26.05%-25.74%
AGRXAgile Therapeutic...-4.64%132.26%193.88%
AMAGAMAG Pharmaceutic...-28.34%-39.87%-52.67%
LCILannett-27.83%11.37%-58.24%
PFEPfizer3.94%3.67%24.74%

TherapeuticsMD competitors

We chose a few stocks to conform a list of TherapeuticsMD competitors to review if you are interested in investing in TXMD: